权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Reversing Immune Dysfunction for HIV-1 Eradication

逆转免疫功能障碍以根除 HIV-1

基本信息

批准号：
10313784
负责人：
SUMIT K CHANDA
金额：
$ 500.18万
依托单位：
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-16 至 2021-10-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10313784
关键词：
AIDS/HIV problem Acquired Immunodeficiency Syndrome Address Adult Age Allogenic Anatomy Antibodies Antiviral Agents Automobile Driving B-Lymphocytes BCL2 gene Biology Biomedical Research CCR5 gene CD4 Positive T Lymphocytes CD8-Positive T-Lymphocytes Cell Therapy Cell physiology Cells Clinic Clinical Clinical Trials Clustered Regularly Interspaced Short Palindromic Repeats Collaborations Combined Modality Therapy Communities Community Outreach Complement Containment Development Effector Cell Engineering Engraftment Ensure Epigenetic Process FDA approved FRAP1 gene Feedback Future Genes Genetic Goals HIV HIV Infections HIV-1 Homeostasis Human Immune Immune System Diseases Immune response Immune system Immunology Immunomodulators Individual Infection Infrastructure Innate Immune Response Institution Interruption Intervention Knowledge Laboratory Research Ligands Maintenance Mediating Metabolic Control Modeling Molecular Morbidity - disease rate Natural Immunity Natural Killer Cells Outcome Outcome Study Pathway interactions Patients Pharmacology Proviruses Reagent Recording of previous events Research Resources Scientist Shapes Systems Biology T memory cell T-Lymphocyte Testing Therapeutic Time Transforming Growth Factor beta Translations Tumor Debulking Universities Viral Viral reservoir Virus Virus Latency Virus Replication Voice Work adaptive immune response antiretroviral therapy base cohort collaboratory design drug repurposing experience gut microbiome high risk host microbiome immune function imprint improved outcome in vivo in vivo evaluation inhibitor/antagonist innovation latent HIV reservoir mathematical model member metabolome microbiome monocyte mortality neutralizing antibody neutrophil novel novel strategies novel therapeutic intervention outreach pandemic disease pre-clinical preservation prevent receptor recruit restorative treatment stem success therapy adherence tool viral rebound virology

项目摘要

PROJECT SUMMARY Although the rate of new HIV infections has decreased, containment and eventual eradication of the HIV pandemic remains a top priority in contemporary biomedical research. One of the major challenges to HIV cure is the need to restore normal immune function in order to effectively eliminate the established viral reservoir. We have assembled in RID-HIV: “Reversing Immune Dysfunction for HIV-1 eradication”, basic and clinical scientists with expertise in virology, immunology, microbiome biology, epigenetics, and systems biology. In addition, Merck Research Laboratories will invest significant intellectual, human and material resources to complement the efforts of the academic scientists. The RID-HIV Collaboratory will collectively function to explore the underlying basis of the immune dysregulation in HIV-infected individuals and the impact it has on reservoir persistence and viral rebound control. We will test for the first time several innovative concepts, including identifying epigenetic mechanisms imprinted by the microbiome and host and bacterial metabolomes that prevents the development of effective innate and adaptive immune responses that can control the size, quality and anatomical localization of the HIV reservoir. The overarching goal of the RID-HIV Collaboratory is to provide preclinical in vivo proof-of- concept for a therapeutic paradigm that encompasses immune restorative treatments, used in concert with enhanced viral reactivation and elimination strategies, in order to deliver a HIV-1 cure. We propose three highly integrated and complementary scientific Research Foci (RFs), to be supported by rigorous and iterative modeling of outcomes and shaped by our outreach to the HIV community. In RF1 we will investigate the mechanisms whereby host- and microbiome-derived metabolites impact innate immune responses and influence the maintenance of the latent viral reservoir. In RF2 we will pursue the hypothesis that in ART/ATI clinical cohorts, metabolites that govern innate immunity shape the adaptive immune responses that could prevent viral rebound upon treatment interruption. In addition, we will evaluate the capacity of engineered allogenic stem memory T cells to provide superior cognate help to promote the effector functions of antiviral CD8 T cells, and will assess the ability of FDA-approved and novel immune modulators to reset this baseline immune dysfunction and enhance the function of this novel cell therapy product. In RF 3 we will optimize a best-in-class latency reversal agent (LRA) and identify clinical-stage molecules with synergistic LRA activity. Clearance of reactivated cells will be enhanced using a novel strategy for NK cell recruitment and by genetically modifying B cells to produce broadly neutralizing HIV-1 antibodies that enhance reservoir clearance. Finally, gene editing will be deployed for in vivo targeting and elimination of latent provirus not amenable to LRAs. The outcomes of studies in RF1, RF2 and RF3 will enable the synthesis of a predictive mathematical model to establish the most likely combinations of therapies to achieve an HIV-1 cure, and which will be tested in a capstone aim to establish proof-of-concept for these strategies in NHP models and to enable translation to the clinic.

项目总结